dr. shum discusses dacomitinib in egfr nsclc
Published 5 years ago • 402 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:01
dr. shum on emerging targeted therapies in egfr-mutant nsclc
-
1:06
dr. shum on patient consultation of osimertinib in nsclc
-
0:58
dr. shum on mechanisms of resistance in oncogene-driven nsclc
-
1:03
dr. wakelee discusses dacomitinib in egfr nsclc
-
1:36
dr. mark kris discusses dacomitinib for patient with egfr-positive lung cancer
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:21
dr. bertino on frontline dacomitinib in metastatic egfr nsclc
-
0:44
dr. mok on dacomitinib for first-line lung cancer treatment
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
0:45
dr. corey langer discusses afatinib in egfr-positive nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
4:38
dacomitinib (egfr inhibitor) for lung cancer patients - what is it?
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
7:59
dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc